Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580813 · ClinicalTrials.gov registry record · NA
Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01580813 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 13 participants.
The verdict
NCT01580813, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of certain fats in their blood. The blood vessels and heart of most of these individuals do not work normally and people with T2DM also have an impaired ability to perform exercise. The purpose of this study is to use the free fatty acid lowering drug, acipimox, to temporarily decrease the level of fat in the bloodstream of people with T2DM and observe the physiological changes to blood vessel function and exercise capacity and insulin sensitivity. This will help the investigators to understand ways of improving blood vessel function and the ability to exercise effectively in people who are overweight or have T2DM.
Interventions
- DRUG Placebo
- DRUG Acipimox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-06-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01580813
The ClinicalTrials.gov registry entry for NCT01580813 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01580813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01580813 about?
NCT01580813 is a clinical study titled "Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes". People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of certain fats in their blood. The blood vessels and heart of most of these individuals do not work normally and people with T2DM also have an impaired ability to perform exercise. The purpose of this study is ...
What is the current status of trial NCT01580813?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2011-06. Estimated completion is 2015-06-05.
What interventions are being tested in trial NCT01580813?
The interventions under investigation include: Placebo (DRUG), Acipimox (DRUG).
Who is sponsoring clinical trial NCT01580813?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.